Guardant Health (GH) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Guardant Health (GH) right now is Shield colorectal screening ramp: Shield is the first FDA-approved blood test for primary colorectal cancer screening, and screening revenue jumped to ~$41.6 million in Q1 2026 from ~$5.7 million a year earlier on ~44,000 tests. Revenue (Q1 2026 quarterly) is ~$302 million, up 48% year over year. If that keeps playing out, the setup is favourable; the risk to it is guardant is unprofitable and cash-consumptive, so it depends on the Shield launch converting into durable, reimbursed volume rather than one-off wins. No one can predict where GH trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Guardant Health (GH) higher?
1. Shield colorectal screening ramp
Shield is the first FDA-approved blood test for primary colorectal cancer screening, and screening revenue jumped to ~$41.6 million in Q1 2026 from ~$5.7 million a year earlier on ~44,000 tests. Inclusion in updated American Cancer Society guidelines, a $1,495 Medicare ADLT reimbursement rate, TRICARE military coverage, distribution through Quest Diagnostics, and a July 2026 UnitedHealth coverage decision all widen access. The bet is that a blood draw reaches the roughly one-third of eligible adults who skip colonoscopy and stool tests.
2. Core oncology growth and leverage
The oncology franchise (Guardant360 for therapy selection and Reveal for minimal residual disease) grew revenue 36% year over year with ~47% volume growth in Q1 2026. Management guides to oncology volume growth above 35% and revenue growth of ~28 to 29% for the full year. This established, higher-margin business is meant to fund the screening land grab and is expected to be free-cash-flow positive on its own.
3. Path to cash-flow breakeven
Guardant is targeting company-wide cash-flow breakeven by the end of 2027, with the core business excluding screening expected to turn cash-positive sooner. Screening drove roughly $220 million of 2025 cash burn and a similar level is expected in 2026. Lowering the cost per Shield test toward ~$200 and scaling test volume are the levers management points to for closing the gap.
4. Biopharma, data, and AI optionality
The Biopharma and Data segment (~$53 million in Q1 2026, up 17%) sells companion-diagnostic work, real-world data, and partnerships to drugmakers, adding a revenue stream tied to industry research budgets. Guardant also markets AI analytics layered on its large dataset of tested patients, which could support new products in monitoring and multi-cancer detection over time.
What could weigh on GH?
Guardant is unprofitable and cash-consumptive, so it depends on the Shield launch converting into durable, reimbursed volume rather than one-off wins. Reimbursement is the central swing factor: coverage decisions, guideline inclusion, and per-test pricing (the $1,495 Medicare rate, private payer terms) can move sharply and are outside the company's control. Competition is intense from Exact Sciences (Cologuard in colorectal screening), Natera (minimal residual disease), and Roche's Foundation Medicine (genomic profiling), which pressures pricing and share. Shield's clinical sensitivity, roughly 84% overall but lower for early-stage and precancerous lesions, invites scrutiny versus colonoscopy. The stock also trades at a high price-to-sales multiple, so any slip in growth or the breakeven timeline can trigger large swings.
Where GH trades today
A forecast starts from where the stock actually is. These are GH's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for GH as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a GH forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the GH guide and whether GH is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the GH outlook
The bottom line: what is driving Guardant Health (GH) is Shield colorectal screening ramp, with revenue (q1 2026 quarterly) at ~$302 million, up 48% year over year. If that keeps playing out the setup is favourable; the risk is guardant is unprofitable and cash-consumptive, so it depends on the Shield launch converting into durable, reimbursed volume rather than one-off wins. No one can predict the price, so treat any GH forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around GH with Walnut
Use Guardant Health as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Guardant Health (GH)?
+
No one can reliably predict where GH will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Guardant Health higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive GH higher?
+
The main growth drivers are Shield colorectal screening ramp; Core oncology growth and leverage; Path to cash-flow breakeven. Whether they play out is the real question, not a guaranteed path.
What are the risks to GH?
+
Guardant is unprofitable and cash-consumptive, so it depends on the Shield launch converting into durable, reimbursed volume rather than one-off wins. Reimbursement is the central swing factor: coverage decisions, guideline inclusion, and per-test pricing (the $1,495 Medicare rate, private payer terms) can move sharply and are outside the company's control. Competition is intense from Exact Sciences (Cologuard in colorectal screening), Natera (minimal residual disease), and Roche's Foundation Medicine (genomic profiling), which pressures pricing and share. Shield's clinical sensitivity, roughly 84% overall but lower for early-stage and precancerous lesions, invites scrutiny versus colonoscopy. The stock also trades at a high price-to-sales multiple, so any slip in growth or the breakeven timeline can trigger large swings.
Will GH stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Guardant Health's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is GH a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the GH "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.